The last full week of October was action-packed for Biogen Inc., with updated Phase II data for the Alzheimer's drug BAN2401 and progress for a number of other neuroscience assets in the pipeline, but also two mid-stage failures – vixotrigine in sciatica and dapirolizumab pegol in lupus.
The pipeline update comes at a time of concern about coming competition for the company's rare disease drug Spinraza and...